NADMED Ltd. ads

Accurate quantification of NAD⁺ and NADH in human blood requires validated methodology. In this white paper, NADMED evaluated the suitability of two commonly used dried blood spot (DBS) cards for quantitative measurement of NAD⁺ and NADH, using paired comparisons with whole blood samples. Download the full white paper to review the experimental design, extraction methodology, and comparative data. Backed by controlled laboratory validation.

Dried blood spot sampling offers practical advantages for remote collection. But is it suitable for quantitative NAD⁺ and NADH diagnostics? In this white paper, NADMED conducted a comparative evaluation of DBS cards versus whole blood measurement. The study concludes that current DBS-based NAD⁺ measurement is not yet reliable enough for diagnostic purposes due to the risk of underestimation. Download the white paper for full data and discussion.

Win $30,000 in products and services for your NAD research! The NADMED Award is still open for applications, but only until January 31st. We’re offering $30,000 worth of NADMED products and services to support the most promising research plan in NAD and redox metabolism. Whether you're working in academia, diagnostics, or applied research, this is your chance to accelerate your work with the gold standard in redox measurement. Don't miss out! The clock is ticking, and we’d love to see your proposal. Apply now or share with a colleague: https://lnkd.in/dhhpxZvf #NADMED #NADResearch #Glutathione #RedoxBiology #LifeSciences #ResearchGrant #NAD #CallForApplications #InnovationInScience

🌟 NADMED Award 2026 – $30,000 for Advancing Science Through Redox and Metabolomics Innovation We are pleased to announce the launch of the NADMED Award 2026, created to support pioneering work in NAD metabolism, redox biology, and metabolomics research. The award provides up to $30,000 in NADMED technology and expert collaboration to enable researchers, clinicians, and biotech innovators to accelerate high-impact projects. Our analytical platform is the only method capable of reliably quantifying all NAD forms (NAD⁺, NADH, NADP⁺, NADPH) and glutathione (GSH/GSSG) from blood or tissue, offering a comprehensive view of redox status. Who can apply? Researchers and teams from academia, clinical laboratories, hospitals, biotech, and pharmaceutical companies worldwide. Key dates Application form available: 15 December 2025 Application period: 1–31 January 2026 Learn more about the award and eligibility criteria here: 🔗 https://lnkd.in/dmvv9Fru We look forward to supporting innovative work that advances our understanding of human metabolism and contributes to the future of precision diagnostics. #NADMED #NAD #NADMEDaward #RedoxBiology #Metabolomics #PrecisionMedicine #BiotechInnovation

NADMED is conducting an executive search for its next CEO as we enter a new phase of global growth. If you have senior leadership experience in biotech, diagnostics, or life sciences, explore the full opportunity in our executive brief.

NADMED is seeking an experienced life sciences leader for the CEO role. See the executive brief for responsibilities, requirements, and company details.